Advertisement

Molecular Medicine

, Volume 18, Issue 2, pp 297–313 | Cite as

Hematopoietic CC-Chemokine Receptor 2 (CCR2) Competent Cells Are Protective for the Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer’s Disease

  • Gaëlle Naert
  • Serge Rivest
Invited Research Article

Abstract

Monocytes emigrate from bone marrow, can infiltrate into brain, differentiate into microglia and clear amyloid β (Aβ) from the brain of mouse models of Alzheimer’s disease (AD). Here we show that these mechanisms specifically require CC-chemokine receptor 2 (CCR2) expression in bone marrow cells (BMCs). Disease progression was exacerbated in APPSwe/PS1 mice (transgenic mice expressing a chimeric amyloid precursor protein [APPSwe] and human presenilin 1 [PS1]) harboring CCR2-deficient BMCs. Indeed, transplantation of CCR2-deficient BMCs enhanced the mnesic deficit and increased the amount of soluble Aβ and expression of transforming growth factor (TGF)-β1 and TGF-β receptors. By contrast, transplantation of wild-type bone marrow stem cells restored memory capacities and diminished soluble Aβ accumulation in APPSwe/PS1 and APPSwe/PS1/CCR2−/− mice. Finally, gene therapy using a lentivirus-expressing CCR2 transgene in BMCs prevented cognitive decline in this mouse model of AD. Injection of CCR2 lentiviruses restored CCR2 expression and functions in monocytes. The presence of these cells in the brain of nonirradiated APPSwe/PS1/CCR2−/− mice supports the concept that they can be used as gene vehicles for AD. Decreased CCR2 expression in bone marrow-derived microglia may therefore play a major role in the etiology of this neurodegenerative disease.

Notes

Acknowledgments

The Canadian Institutes in Health Research and Neuroscience Canada (Brain Repair Program) supported this research. G Naert was supported by a postdoctoral fellowship from the Alzheimer Society of Canada. S Rivest is a Canadian Research Chair in Neuroimmunology. We acknowledge the contribution of Mohammed Filali, Martine Lessard, Paul Préfontaine, Denis Soulet and Marie-Michèle Plante for technical help. We are grateful to Matthias Mack (Universitätsklinikum Regensburg Innere Medizin II/Nephrologie-Transplantation, Regensburg, Germany) for the gift of the anti-CCR2 antibody (Ab MC-21).

References

  1. 1.
    Lesne S, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 440:352–7.CrossRefGoogle Scholar
  2. 2.
    Haass C, Selkoe DJ. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8:101–12.CrossRefGoogle Scholar
  3. 3.
    Selkoe DJ. (2002) Alzheimer’s disease is a synaptic failure. Science. 298:789–91.CrossRefGoogle Scholar
  4. 4.
    Perry VH, Gordon S. (1988) Macrophages and microglia in the nervous system. Trends Neurosci. 11:273–7.CrossRefGoogle Scholar
  5. 5.
    Dickson DW, et al. (1988) Alzheimer’s disease: a double-labeling immunohistochemical study of senile plaques. Am. J. Pathol. 132:86–101.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Haga S, Akai K, Ishii T. (1989) Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: an immunohistochemical study using a novel monoclonal antibody. Acta. Neuropathol. 77:569–75.CrossRefGoogle Scholar
  7. 7.
    Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron. 49:489–502.CrossRefGoogle Scholar
  8. 8.
    Stalder AK, et al. (2005) Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25:11125–32.CrossRefGoogle Scholar
  9. 9.
    Malm TM, et al. (2005) Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis. 18:134–42.CrossRefGoogle Scholar
  10. 10.
    Kaur C, Ling EA, Wong WC. (1987) Origin and fate of neural macrophages in a stab wound of the brain of the young rat. J. Anat. 154:215–27.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Ling EA. (1979) Transformation of monocytes into amoeboid microglia in the corpus callosum of postnatal rats, as shown by labelling monocytes by carbon particles. J. Anat. 128:847–58.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Soulet D, Rivest S. (2008) Bone-marrow-derived microglia: myth or reality? Curr. Opin. Pharmacol. 8:508–18.CrossRefGoogle Scholar
  13. 13.
    Geissmann F, Jung S, Littman DR. (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 19:71–82.CrossRefGoogle Scholar
  14. 14.
    Auffray C, et al. (2009) CX3CR1+ CD115+CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. J. Exp. Med. 206:595–606.CrossRefGoogle Scholar
  15. 15.
    Charo IF, Ransohoff RM. (2006) The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354:610–21.CrossRefGoogle Scholar
  16. 16.
    Luster AD. (1998) Chemokines: chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436–45.CrossRefGoogle Scholar
  17. 17.
    Mack M, et al. (2001) Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166:4697–704.CrossRefGoogle Scholar
  18. 18.
    Saederup N, et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One. 5:e13693.Google Scholar
  19. 19.
    Si Y, Tsou CL, Croft K, Charo IF. (2010) CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. J. Clin. Invest. 120:1192–203.CrossRefGoogle Scholar
  20. 20.
    Engel DR, et al. (2008) CCR2 mediates homeostatic and inflammatory release of Gr1(high) monocytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection. J. Immunol. 181:5579–86.CrossRefGoogle Scholar
  21. 21.
    Serbina NV, Pamer EG. (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7:311–7.CrossRefGoogle Scholar
  22. 22.
    Tsou CL, et al. (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117:902–9.CrossRefGoogle Scholar
  23. 23.
    Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. (2000) Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192:1075–80.CrossRefGoogle Scholar
  24. 24.
    Babcock AA, Kuziel WA, Rivest S, Owens T. (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23:7922–30.CrossRefGoogle Scholar
  25. 25.
    D’Mello C, Le T, Swain MG. (2009) Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci. 29:2089–102.CrossRefGoogle Scholar
  26. 26.
    D’Ambrosio D, Panina-Bordignon P, Sinigaglia F. (2003) Chemokine receptors in inflammation: an overview. J. Immunol. Meth. 273:3–13.CrossRefGoogle Scholar
  27. 27.
    Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. (1990) Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am. J. Pathol. 136:1229–33.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Cushing SD, et al. (1990) Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 87:5134–8.CrossRefGoogle Scholar
  29. 29.
    Smits HA, et al. (2002) Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127:160–8.CrossRefGoogle Scholar
  30. 30.
    Glabinski AR, et al. (1996) Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J. Immunol. 156:4363–8.PubMedGoogle Scholar
  31. 31.
    El Khoury JB, et al. (2003) CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197:1657–66.CrossRefGoogle Scholar
  32. 32.
    Meda L, et al. (1995) Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 374:647–50.CrossRefGoogle Scholar
  33. 33.
    Deshmane SL, Kremlev S, Amini S, Sawaya BE. (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29:313–26.CrossRefGoogle Scholar
  34. 34.
    Ishizuka K, et al. (1997) Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psych. Clin. Neurosci. 51:135–8.CrossRefGoogle Scholar
  35. 35.
    Grammas P, Ovase R. (2001) Inflammatory factors are elevated in brain microvessels in Alzheimer’s disease. Neurobiol. Aging. 22:837–42.CrossRefGoogle Scholar
  36. 36.
    El Khoury J, et al. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13:432–8.CrossRefGoogle Scholar
  37. 37.
    Naert G, Rivest S. (2011) The role of microglial cell subsets in Alzheimer’s disease. Curr. Alzheimer Res. 8:151–5.CrossRefGoogle Scholar
  38. 38.
    Simard AR, Rivest S. (2006) Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer’s disease. Mol. Psychiatry. 11:327–35.CrossRefGoogle Scholar
  39. 39.
    Richard KL, Filali M, Prefontaine P, Rivest S. (2008) Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1–42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J. Neurosci. 28:5784–93.CrossRefGoogle Scholar
  40. 40.
    Nadeau S, Rivest S. (2000) Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor kappa B activity in the brain during endotoxemia. J. Neurosci. 20:3456–68.CrossRefGoogle Scholar
  41. 41.
    Laflamme N, Lacroix S, Rivest S. (1999) An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J. Neurosci. 19:10923–30.CrossRefGoogle Scholar
  42. 42.
    Laflamme N, Rivest S. (2001) Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. FASEB J. 15:155–63.CrossRefGoogle Scholar
  43. 43.
    Naert G, Laflamme N, Rivest S. (2009) Toll-like receptor 2-independent and MyD88-dependent gene expression in the mouse brain. J. Innate. Immun. 1:480–93.CrossRefGoogle Scholar
  44. 44.
    Paxinos G, Franklin KBJ. (2001) The mouse brain in stereotaxic coordinates. 2nd ed. San Diego: Academic Press. [186 pp].Google Scholar
  45. 45.
    Boissonneault V, et al. (2009) Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer’s disease. Brain. 132:1078–92.CrossRefGoogle Scholar
  46. 46.
    Lue LF, et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am. J. Pathol. 155:853–62.CrossRefGoogle Scholar
  47. 47.
    McLean CA, et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46:860–6.CrossRefGoogle Scholar
  48. 48.
    Cheng IH, et al. (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282:23818–28.CrossRefGoogle Scholar
  49. 49.
    Jia T, et al. (2008) Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. J. Immunol. 180:6846–53.CrossRefGoogle Scholar
  50. 50.
    Lesne S, Kotilinek L, Ashe KH. (2008) Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience. 151:745–9.CrossRefGoogle Scholar
  51. 51.
    Cleary JP, et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8:79–84.CrossRefGoogle Scholar
  52. 52.
    Klyubin I, et al. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28:4231–7.CrossRefGoogle Scholar
  53. 53.
    Hung LW, et al. (2008) Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J. Neurosci. 28:11950–8.CrossRefGoogle Scholar
  54. 54.
    Shankar GM, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 14:837–42.CrossRefGoogle Scholar
  55. 55.
    Steinerman JR, et al. (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch. Neurol. 65:906–12.CrossRefGoogle Scholar
  56. 56.
    Bolmont T, et al. (2008) Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci. 28:4283–92.CrossRefGoogle Scholar
  57. 57.
    Lee S, et al. (2010) CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer’s disease mouse models. Am. J. Pathol. 177:2549–62.CrossRefGoogle Scholar
  58. 58.
    Liu Z, Condello C, Schain A, Harb R, Grutzendler J. (2010) CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J. Neurosci. 30:17091–101.CrossRefGoogle Scholar
  59. 59.
    Mandrekar S, et al. (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 29:4252–62.CrossRefGoogle Scholar
  60. 60.
    Magga J, et al. (2011) Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer’s disease. J. Cell. Mol. Med. 2011, Jul 21 [Epub ahead of print].Google Scholar
  61. 61.
    Lebson L, et al. (2010) Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J. Neurosci. 30:9651–8.CrossRefGoogle Scholar
  62. 62.
    Mousseau DD, et al. (2003) A direct interaction between transforming growth factor (TGF)-betas and amyloid-beta protein affects fibrillogenesis in a TGF-beta receptor-independent manner. J. Biol. Chem. 278:38715–22.CrossRefGoogle Scholar
  63. 63.
    Brionne TC, Tesseur I, Masliah E, Wyss-Coray T. (2003) Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron. 40:1133–45.CrossRefGoogle Scholar
  64. 64.
    Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E. (2000) Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am. J. Path. 156:139–50.CrossRefGoogle Scholar
  65. 65.
    Wyss-Coray T, et al. (2001) TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7:612–8.CrossRefGoogle Scholar
  66. 66.
    Wyss-Coray T, et al. (1997) Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer’s disease. Nature. 389:603–6.CrossRefGoogle Scholar
  67. 67.
    Town T, et al. (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimerlike pathology. Nat. Med. 14:681–7.CrossRefGoogle Scholar
  68. 68.
    Deane R, et al. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 43:333–44.CrossRefGoogle Scholar
  69. 69.
    Shibata M, et al. (2000) Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489–99.CrossRefGoogle Scholar
  70. 70.
    Deane R, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9:907–13.CrossRefGoogle Scholar
  71. 71.
    DeMattos RB, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 98:8850–5.CrossRefGoogle Scholar
  72. 72.
    Lemere CA, et al. (2003) Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol. Dis. 14:10–8.CrossRefGoogle Scholar
  73. 73.
    Holtzman DM, Bales KR, Paul SM, DeMattos RB. (2002) Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer’s disease. Adv. Drug Deliv. Rev. 54:1603–13.CrossRefGoogle Scholar
  74. 74.
    Cartier N, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818–23.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Laboratory of Endocrinology and Genomics, Centre Hospitalier de l’Université Laval (CHUL) Research Center and Department of Molecular Medicine, Faculty of MedicineLaval UniversityQuébecCanada
  2. 2.Laboratory of Molecular Endocrinology, CHUL Research Center and Department of Anatomy and PhysiologyLaval UniversityQuébecCanada

Personalised recommendations